Favourable results for Elocta® when evaluating treatment options for haemophilia A
The international medical journal Advances in Therapy has recently published data evaluating treatment options for haemophilia A. The journal reported that when using individualised prophylaxis with extended half-life (EHL) products, Elocta® (rFVIIIFc) resulted in lower annual bleed rates when compared to Jivi™ (BAY 94-9027). The report was based on an indirect comparison of pivotal clinical trial data in adults. “We are conscious of the difficulties to conduct clinical head-to-head studies in a rare disease setting such as